コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tients with refractory bladder pain syndrome/interstitial cystitis.
2 and maintenance of painful bladder syndrome/interstitial cystitis.
3 led protein and is a potential biomarker for interstitial cystitis.
4 dder hyperreflexia in the clinical syndrome, interstitial cystitis.
5 lion people in the United States suffer from interstitial cystitis, a chronic painful urinary bladder
6 overactive bladder, urinary incontinence and interstitial cystitis (also known as bladder pain syndro
7 users of PPS compared with those using other interstitial cystitis and bladder pain drugs (proportion
8 users of PPS compared with those using other interstitial cystitis and bladder pain drugs, respective
9 eral pain in such conditions as renal colic, interstitial cystitis and inflammatory bowel disease by
11 , celiac disease, acquired hemolytic anemia, interstitial cystitis, and Sjogren's syndrome had higher
12 with the literature on bladder pain syndrome/interstitial cystitis, and the implications for their pa
13 emporomandibular disorder, tension headache, interstitial cystitis, and the postconcussion syndrome.
14 rotoxin for refractory bladder pain syndrome/interstitial cystitis appears promising, larger-scale st
16 nderlying chronic bladder conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and
20 Chronic visceral pain disorders, such as interstitial cystitis/bladder pain syndrome (IC/BPS), ar
21 of functional pelvic pain disorders such as interstitial cystitis/bladder pain syndrome (IC/BPS).
22 d with exacerbated symptoms in patients with interstitial cystitis/bladder pain syndrome (IC/BPS).
23 n shown to improve symptoms in patients with interstitial cystitis/bladder pain syndrome (IC/BPS); ho
24 ic prostatitis/chronic pelvic pain syndrome, interstitial cystitis/bladder pain syndrome and chronic
25 vic pain syndrome (UCPPS), which encompasses interstitial cystitis/bladder pain syndrome and chronic
26 few approved therapies for the treatment of interstitial cystitis/bladder pain syndrome and chronic
31 h drugs taken for the following indications: interstitial cystitis, cystitis, bladder disorder, or bl
32 During the past year the association with interstitial cystitis has been explored, and neurally me
33 ecurrent urinary tract infections (UTIs) and interstitial cystitis have been studied utilizing 16S rR
35 f the urinary bladder, including Hunner-type interstitial cystitis (HIC), bacillus Calmette-Guerin (B
39 ptide elevated in the urine of patients with interstitial cystitis (IC)-a chronic, painful bladder di
41 includes bladder problems (possibly urinary interstitial cystitis [IC]), thyroid disorders, chronic
45 unified understanding of the pathogenesis of interstitial cystitis is emerging and this will hopefull
46 ive from which we view bladder pain syndrome/interstitial cystitis is evolving, as is apparent in the
48 ch as overactive bladder syndrome (OABS) and interstitial cystitis/painful bladder syndrome (IC/PBS)
49 is a sialoglycopeptide urinary biomarker of interstitial cystitis/painful bladder syndrome (IC/PBS),
51 continence, lower urinary tract symptoms and interstitial cystitis/painful bladder syndrome, as well
52 r from urological symptoms characteristic of interstitial cystitis/painful bladder syndrome, which ma
53 ptide that is secreted by bladder cells from interstitial cystitis patients and is a potent inhibitor
54 nterstitial cystitis, we reported that 7% of interstitial cystitis patients studied had autoantibodie
56 ons including immediate hypersensitivity and interstitial cystitis, their physiological role in the b
57 sing an autoimmune serum from a patient with interstitial cystitis, we have identified and partially
58 in the chronic inflammatory bladder disease interstitial cystitis, we reported that 7% of interstiti